ArticleDiabetes, obesity & metabolism2025
Real-world insights into incretin-based therapy: Associations between changes in taste perception and appetite regulation in individuals with obesity and overweight: A cross-sectional study.
Article in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Effects of Oral Semaglutide on Dietary Intake and Body Composition in Japanese People With Type 2 Diabetes: A Prospective Observational Study in Clinical Practice.Endocrinology, diabetes & metabolism · 2026Observational
- Chronic semaglutide alters ingestive behavior without impairing taste function in mice.Molecular metabolism · 2026Article
- Pre-Treatment Concerns and Their Association With Functioning and Well-Being During Incretin-Based Therapy: A Cross-Sectional Study.Diabetes, obesity & metabolism · 2026Article
- Associations between Eating Behaviours and Psychological Characteristics with Body Mass Index Change and Appetite-Related Changes during Incretin-Based Therapy.Obesity facts · 2026Article
- Real-world insights into incretin-based therapy: Associations between changes in taste perception and appetite regulation in individuals with obesity and overweight: A cross-sectional study.Diabetes, obesity & metabolism · 2025Article
- Potential role of glucagon like peptide 1 in taste receptors.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThis cross-sectional study examined associations between self-reported taste perception changes and appetite-related outcomes in individuals with obesity treated with glucagon-like peptide-1 receptor agonist (GLP-1 RAS) or dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAS in real-world conditions. MATERIALS AND
methodsFour hundred and eleven adults on Wegovy® (n = 217), Ozempic® (n = 148) and Mounjaro® (n = 46) completed an online survey assessing sociodemographic, anthropometric and sensory changes and appetite-related outcomes. Multivariable logistic regression was used to assess associations between taste changes and satiety, appetite and craving.
resultsParticipants (69.6% female; median age 39 [interquartile range, IQR 33-47]) had baseline body mass index (BMI) of 35.6 (Wegovy®), 34.7 (Ozempic®) and 36.2 kg/m
conclusionsSelf-reported changes in taste perception during GLP-1 or dual GIP/GLP-1 RAS therapy were associated with favourable appetite-related outcomes, suggesting a potential mechanism contributing to treatment response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.